Y. Li

Identification of lung cancer oncogenes based on the mRNA expression and single nucleotide polymorphism profile data.

Y. Chen, R. Li, Y F Li, 2015, Neoplasma.

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.

K. Weinfurt, K. Schulman, F. Saad, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment

Y. Wang, J. Sun, R. Kong, 2018, Clinical and Translational Oncology.

Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients

W. He, J. Zhang, Y. Wang, 2015, Clinical and Translational Oncology.

A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors.

A. Tolcher, Y. Zhai, Y. Huang, 2019 .

73P Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis

J. Carles, J. Bono, S. Oudard, 2021, Annals of Oncology.

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

B. Monk, A. Oza, J. Berek, 2019, Gynecologic Oncology.

Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients

J. Zou, Y. Liu, Y. Li, 2020, Clinical and Translational Oncology.

975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma

J. Berlin, M. Blaney, J. Grewal, 2020 .